25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Alaunos Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Alaunos together

I guess you are interested in Alaunos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alaunos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alaunos Therapeutics Inc

I send you an email if I find something interesting about Alaunos Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Alaunos (30 sec.)










1.2. What can you expect buying and holding a share of Alaunos? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$1.70
Expected worth in 1 year
$2.53
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.83
Return On Investment
39.3%

For what price can you sell your share?

Current Price per Share
$2.12
Expected price per share
$1.95 - $5.6
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alaunos (5 min.)




Live pricePrice per Share (EOD)
$2.12
Intrinsic Value Per Share
$65.64 - $366.73
Total Value Per Share
$67.34 - $368.43

2.2. Growth of Alaunos (5 min.)




Is Alaunos growing?

Current yearPrevious yearGrowGrow %
How rich?$2.7m$25.9m-$21.5m-488.7%

How much money is Alaunos making?

Current yearPrevious yearGrowGrow %
Making money-$2.9m-$9m$6.1m209.0%
Net Profit Margin-245,181.3%-77,097.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Alaunos (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#737 / 949

Most Revenue
#779 / 949

Most Profit
#353 / 949

Most Efficient
#944 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alaunos?

Welcome investor! Alaunos's management wants to use your money to grow the business. In return you get a share of Alaunos.

First you should know what it really means to hold a share of Alaunos. And how you can make/lose money.

Speculation

The Price per Share of Alaunos is $2.12. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alaunos.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alaunos, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.70. Based on the TTM, the Book Value Change Per Share is $0.21 per quarter. Based on the YOY, the Book Value Change Per Share is $0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alaunos.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.70-33.2%-1.84-86.8%-0.58-27.4%-0.53-25.1%-0.36-17.0%
Usd Book Value Change Per Share-0.65-30.8%0.219.8%0.188.5%0.052.5%0.031.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.2%0.010.5%
Usd Total Gains Per Share-0.65-30.8%0.219.8%0.188.5%0.062.8%0.042.0%
Usd Price Per Share3.22-1.45-0.48-1.80-3.85-
Price to Earnings Ratio-1.14--0.46--0.20--4.49--8.79-
Price-to-Total Gains Ratio-4.92--1.98--0.47--15.04--25.79-
Price to Book Ratio1.89-0.70-0.28-3.17-9.26-
Price-to-Total Gains Ratio-4.92--1.98--0.47--15.04--25.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.12
Number of shares471
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.05
Usd Total Gains Per Share0.210.06
Gains per Quarter (471 shares)98.0427.65
Gains per Year (471 shares)392.15110.59
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103923829102101
2078477418203212
301176116627305323
401569155836407434
501961195045508545
602353234254610656
702745273463712767
803137312671813878
903529351880915989
100392139108910171100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%2.092.00.02.1%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%10.030.00.025.0%25.067.02.026.6%
Dividend per Share0.00.04.00.0%1.00.011.08.3%2.00.018.010.0%7.00.033.017.5%7.00.087.07.4%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%10.030.00.025.0%25.067.02.026.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alaunos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6540.208-414%0.180-464%0.054-1312%0.033-2055%
Book Value Per Share--1.7012.748-38%1.665+2%1.132+50%0.730+133%
Current Ratio--4.2984.637-7%2.733+57%5.142-16%6.122-30%
Debt To Asset Ratio--0.2330.217+7%0.327-29%0.309-25%0.450-48%
Debt To Equity Ratio--0.3030.278+9%0.505-40%0.460-34%0.983-69%
Dividend Per Share----0%-0%0.005-100%0.010-100%
Enterprise Value--6013031.4403162315.150+90%16366995.330-63%333598756.899-98%571370039.351-99%
Eps---0.704-1.839+161%-0.581-18%-0.532-24%-0.360-49%
Ev To Ebitda Ratio---1.334inf+inf%-0.524-61%inf+inf%inf+inf%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share--18.0472.797+545%-0.481+103%0.424+4157%0.175+10239%
Free Cash Flow To Equity Per Share--2.468-1.098+144%-0.622+125%-0.352+114%-0.167+107%
Gross Profit Margin--1.0001.0010%1.173-15%1.184-16%1.092-8%
Intrinsic Value_10Y_max--366.729--------
Intrinsic Value_10Y_min--65.638--------
Intrinsic Value_1Y_max--7.922--------
Intrinsic Value_1Y_min--1.708--------
Intrinsic Value_3Y_max--45.771--------
Intrinsic Value_3Y_min--9.379--------
Intrinsic Value_5Y_max--110.108--------
Intrinsic Value_5Y_min--21.648--------
Market Cap3394650.000-52%5156031.4402321815.400+122%7495245.330-31%294217856.949-98%541188864.376-99%
Net Profit Margin----2451.8130%-770.9720%-647.5750%-339.4400%
Operating Margin----491.0630%-690.5340%-239.2620%-135.3250%
Operating Ratio---1349.188-100%822.455-100%437.383-100%234.726-100%
Pb Ratio1.246-52%1.8930.703+169%0.280+577%3.168-40%9.255-80%
Pe Ratio-0.753+34%-1.144-0.457-60%-0.202-82%-4.491+293%-8.792+669%
Price Per Share2.120-52%3.2201.450+122%0.480+571%1.799+79%3.846-16%
Price To Free Cash Flow Ratio0.029-52%0.045-0.126+382%-0.242+642%-5.720+12924%-10.064+22662%
Price To Total Gains Ratio-3.242+34%-4.925-1.978-60%-0.471-90%-15.039+205%-25.789+424%
Quick Ratio--2.0382.025+1%2.294-11%4.195-51%5.033-60%
Return On Assets---0.317-0.447+41%-0.273-14%-0.230-28%-0.229-28%
Return On Equity---0.414-0.577+39%-0.397-4%-0.317-23%-0.368-11%
Total Gains Per Share---0.6540.208-414%0.180-464%0.059-1214%0.043-1610%
Usd Book Value--2724000.0004399750.000-38%25903500.000-89%58798250.000-95%51698625.000-95%
Usd Book Value Change Per Share---0.6540.208-414%0.180-464%0.054-1312%0.033-2055%
Usd Book Value Per Share--1.7012.748-38%1.665+2%1.132+50%0.730+133%
Usd Dividend Per Share----0%-0%0.005-100%0.010-100%
Usd Enterprise Value--6013031.4403162315.150+90%16366995.330-63%333598756.899-98%571370039.351-99%
Usd Eps---0.704-1.839+161%-0.581-18%-0.532-24%-0.360-49%
Usd Free Cash Flow--28897000.0004478500.000+545%-7550000.000+126%-8888900.000+131%-9542450.000+133%
Usd Free Cash Flow Per Share--18.0472.797+545%-0.481+103%0.424+4157%0.175+10239%
Usd Free Cash Flow To Equity Per Share--2.468-1.098+144%-0.622+125%-0.352+114%-0.167+107%
Usd Market Cap3394650.000-52%5156031.4402321815.400+122%7495245.330-31%294217856.949-98%541188864.376-99%
Usd Price Per Share2.120-52%3.2201.450+122%0.480+571%1.799+79%3.846-16%
Usd Profit---1127000.000-2945250.000+161%-9099500.000+707%-12618850.000+1020%-18941325.000+1581%
Usd Revenue---1500.000-100%3750.000-100%166500.000-100%534950.000-100%
Usd Total Gains Per Share---0.6540.208-414%0.180-464%0.059-1214%0.043-1610%
 EOD+4 -4MRQTTM+19 -16YOY+14 -215Y+15 -2210Y+15 -22

3.3 Fundamental Score

Let's check the fundamental score of Alaunos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.753
Price to Book Ratio (EOD)Between0-11.246
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.038
Current Ratio (MRQ)Greater than14.298
Debt to Asset Ratio (MRQ)Less than10.233
Debt to Equity Ratio (MRQ)Less than10.303
Return on Equity (MRQ)Greater than0.15-0.414
Return on Assets (MRQ)Greater than0.05-0.317
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Alaunos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.575
Ma 20Greater thanMa 502.304
Ma 50Greater thanMa 1002.365
Ma 100Greater thanMa 2002.677
OpenGreater thanClose2.380
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Alaunos Therapeutics Inc

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2024-12-04 08:26:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Alaunos earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-245,181.3%+245,181.3%
TTM-245,181.3%YOY-77,097.2%-168,084.1%
TTM-245,181.3%5Y-64,757.5%-180,423.8%
5Y-64,757.5%10Y-33,944.0%-30,813.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.0%+108.0%
TTM-245,181.3%-218.6%-244,962.7%
YOY-77,097.2%-210.1%-76,887.1%
5Y-64,757.5%-339.1%-64,418.4%
10Y-33,944.0%-464.5%-33,479.5%
4.3.1.2. Return on Assets

Shows how efficient Alaunos is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • -31.7% Return on Assets means that Alaunos generated $-0.32 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alaunos Therapeutics Inc:

  • The MRQ is -31.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -44.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-31.7%TTM-44.7%+12.9%
TTM-44.7%YOY-27.3%-17.3%
TTM-44.7%5Y-23.0%-21.7%
5Y-23.0%10Y-22.9%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.7%-11.3%-20.4%
TTM-44.7%-11.8%-32.9%
YOY-27.3%-11.3%-16.0%
5Y-23.0%-12.6%-10.4%
10Y-22.9%-14.2%-8.7%
4.3.1.3. Return on Equity

Shows how efficient Alaunos is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • -41.4% Return on Equity means Alaunos generated $-0.41 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alaunos Therapeutics Inc:

  • The MRQ is -41.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -57.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-41.4%TTM-57.7%+16.3%
TTM-57.7%YOY-39.7%-18.0%
TTM-57.7%5Y-31.7%-26.0%
5Y-31.7%10Y-36.8%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-41.4%-14.2%-27.2%
TTM-57.7%-15.9%-41.8%
YOY-39.7%-14.4%-25.3%
5Y-31.7%-18.5%-13.2%
10Y-36.8%-19.5%-17.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alaunos Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Alaunos is operating .

  • Measures how much profit Alaunos makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-49,106.3%+49,106.3%
TTM-49,106.3%YOY-69,053.4%+19,947.2%
TTM-49,106.3%5Y-23,926.2%-25,180.0%
5Y-23,926.2%10Y-13,532.5%-10,393.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM-49,106.3%-313.2%-48,793.1%
YOY-69,053.4%-219.0%-68,834.4%
5Y-23,926.2%-388.9%-23,537.3%
10Y-13,532.5%-495.6%-13,036.9%
4.3.2.2. Operating Ratio

Measures how efficient Alaunos is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1,349.188-1,349.188
TTM1,349.188YOY822.455+526.733
TTM1,349.1885Y437.383+911.804
5Y437.38310Y234.726+202.657
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.340-2.340
TTM1,349.1883.187+1,346.001
YOY822.4553.282+819.173
5Y437.3834.814+432.569
10Y234.7266.494+228.232
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alaunos Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alaunos is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.30 means the company has $4.30 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 4.298. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.637. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.298TTM4.637-0.339
TTM4.637YOY2.733+1.904
TTM4.6375Y5.142-0.505
5Y5.14210Y6.122-0.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2983.645+0.653
TTM4.6373.883+0.754
YOY2.7334.666-1.933
5Y5.1425.964-0.822
10Y6.1226.265-0.143
4.4.3.2. Quick Ratio

Measures if Alaunos is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Quick Ratio of 2.04 means the company can pay off $2.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 2.038. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.025. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.038TTM2.025+0.012
TTM2.025YOY2.294-0.268
TTM2.0255Y4.195-2.169
5Y4.19510Y5.033-0.839
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0383.014-0.976
TTM2.0253.418-1.393
YOY2.2944.456-2.162
5Y4.1955.970-1.775
10Y5.0336.424-1.391
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alaunos Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Alaunos assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alaunos to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Alaunos assets are financed with 23.3% credit (debt) and the remaining percentage (100% - 23.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.233. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.217. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.217+0.016
TTM0.217YOY0.327-0.110
TTM0.2175Y0.309-0.092
5Y0.30910Y0.450-0.141
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2330.350-0.117
TTM0.2170.341-0.124
YOY0.3270.310+0.017
5Y0.3090.365-0.056
10Y0.4500.382+0.068
4.5.4.2. Debt to Equity Ratio

Measures if Alaunos is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alaunos to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.3% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alaunos Therapeutics Inc:

  • The MRQ is 0.303. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.278. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.303TTM0.278+0.025
TTM0.278YOY0.505-0.227
TTM0.2785Y0.460-0.182
5Y0.46010Y0.983-0.523
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3030.394-0.091
TTM0.2780.432-0.154
YOY0.5050.380+0.125
5Y0.4600.451+0.009
10Y0.9830.490+0.493
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alaunos generates.

  • Above 15 is considered overpriced but always compare Alaunos to the Biotechnology industry mean.
  • A PE ratio of -1.14 means the investor is paying $-1.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is -0.753. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.144. Based on the earnings, the company is expensive. -2
  • The TTM is -0.457. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.753MRQ-1.144+0.391
MRQ-1.144TTM-0.457-0.687
TTM-0.457YOY-0.202-0.254
TTM-0.4575Y-4.491+4.034
5Y-4.49110Y-8.792+4.302
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.753-2.315+1.562
MRQ-1.144-2.491+1.347
TTM-0.457-3.156+2.699
YOY-0.202-3.274+3.072
5Y-4.491-6.037+1.546
10Y-8.792-6.785-2.007
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is 0.029. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 0.045. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -0.126. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.029MRQ0.045-0.015
MRQ0.045TTM-0.126+0.171
TTM-0.126YOY-0.242+0.116
TTM-0.1265Y-5.720+5.594
5Y-5.72010Y-10.064+4.344
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.029-2.985+3.014
MRQ0.045-3.361+3.406
TTM-0.126-3.734+3.608
YOY-0.242-4.557+4.315
5Y-5.720-8.327+2.607
10Y-10.064-9.311-0.753
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Alaunos is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.89 means the investor is paying $1.89 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alaunos Therapeutics Inc:

  • The EOD is 1.246. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.893. Based on the equity, the company is underpriced. +1
  • The TTM is 0.703. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.246MRQ1.893-0.647
MRQ1.893TTM0.703+1.190
TTM0.703YOY0.280+0.423
TTM0.7035Y3.168-2.465
5Y3.16810Y9.255-6.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2461.919-0.673
MRQ1.8932.051-0.158
TTM0.7032.374-1.671
YOY0.2802.454-2.174
5Y3.1683.737-0.569
10Y9.2554.378+4.877
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alaunos Therapeutics Inc.

4.8.1. Institutions holding Alaunos Therapeutics Inc

Institutions are holding 12.079% of the shares of Alaunos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30MSD Partners, L.P.6.30820.20621010101010100
2024-09-30Vanguard Group Inc2.832045348453480
2024-09-30Geode Capital Management, LLC1.02016333163330
2024-09-30Morgan Stanley - Brokerage Accounts0.08350133713370
2024-09-30UBS Group AG0.06420102810280
2024-09-30Tower Research Capital LLC0.040.00016406400
2024-09-30Group One Trading, LP0.028604584580
2024-09-30Sugarloaf Wealth Management, LLC0.02720.0003435-2-0.4577
2024-09-30Federation des caisses Desjardins du Quebec0.026604264260
2024-09-30Wells Fargo & Co0.023303733730
2024-09-30BNP Paribas Arbitrage, SA0.021403433430
2024-09-30AdvisorNet Financial, Inc0.01750.0001281-1-0.3546
2024-09-30Bank of Oklahoma National Association0.0041066660
2024-09-30Asset Dedication, LLC0.0034054540
2024-09-30HARBOUR INVESTMENTS, INC.0.0029046460
2024-09-30Newbridge Financial Services Group, Inc.0.0015024240
2024-09-30SignatureFD, LLC0.0014023230
2024-09-30Chilton Capital Management L P0.001016160
2024-09-30West Paces Advisors Inc0.000601000
2024-09-30CWM, LLC duplicate0.00050880
Total 10.50790.2067168259+167530+99.6%

4.9.2. Funds holding Alaunos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.278402047100
2024-10-31Vanguard Total Stock Mkt Idx Inv1.0835017349-7027-28.8275
2024-09-30Fidelity Extended Market Index0.56780.000190927879.4762
2024-06-30SSgA U.S. Total Market Index Strategy0.01910305490642.1788
2024-09-30BlackRock Extended Equity Market K0.18630.00012983-2-0.067
2024-09-30Fidelity Total Market Index0.14840237600
2024-09-30Fidelity Series Total Market Index0.130208200
2024-09-30Fidelity Nasdaq Composite Index0.12540200800
2024-09-30NT Ext Equity Mkt Idx Fd - L0.08470.0001135700
2024-09-30Northern Trust Extended Eq Market Idx0.08470.0001135700
2024-06-30NT Quality SCC US Fund - L0.00810.0004129000
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.06780.0001108600
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.05460.000187520.2291
2024-09-30Spartan Total Market Index Pool E0.0478076500
2024-10-31State St US Extended Mkt Indx NL Cl C0.04650.000174400
2024-09-30BlackRock U.S. Equity Market F0.0452072400
2024-10-31Vanguard U.S. Eq Idx £ Acc0.0313050100
2024-09-30Extended Equity Market Fund M0.02370.0001379-1-0.2632
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.01310.000120900
2024-10-31State St US Ttl Mkt Indx SL Cl I0.0102016300
Total 4.05660.001368865-5335-7.7%

5.3. Insider Transactions

Insiders are holding 14.297% of the shares of Alaunos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-01Kevin S Sr. BoyleSELL45321
2022-11-29Robert W PostmaBUY500097.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets3,550
Total Liabilities826
Total Stockholder Equity2,724
 As reported
Total Liabilities 826
Total Stockholder Equity+ 2,724
Total Assets = 3,550

Assets

Total Assets3,550
Total Current Assets3,550
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 1,683
Other Current Assets 1,867
Total Current Assets  (as reported)3,550
Total Current Assets  (calculated)3,550
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities826
Long-term Liabilities0
Total Stockholder Equity2,724
Total Current Liabilities
Accounts payable 458
Other Current Liabilities 368
Total Current Liabilities  (as reported)826
Total Current Liabilities  (calculated)826
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -919,704
Other Stockholders Equity 922,426
Total Stockholder Equity (as reported)2,724
Total Stockholder Equity (calculated)2,724
+/-0
Other
Capital Stock2
Cash and Short Term Investments 1,683
Common Stock Shares Outstanding 1,601
Liabilities and Stockholders Equity 3,550
Net Debt -1,683
Net Invested Capital 2,724
Net Working Capital 2,724



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-09-302003-06-302003-03-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-09-302000-06-30
> Total Assets 
0
0
0
10
4
3
6
2
1
1
0
0
0
0
0
0
0
1
11,312
9,492
6,308
37,775
35,295
29,512
54,185
48,521
42,801
36,726
29,004
22,458
16,815
12,573
7,873
5,431
8,103
49,736
45,840
74,456
67,450
61,520
130,862
132,821
122,276
108,108
140,873
122,380
105,640
83,404
63,346
45,603
29,478
71,754
63,325
55,348
49,109
45,237
131,648
124,038
173,361
153,724
141,682
128,012
117,122
106,348
94,494
126,813
116,559
105,606
87,461
76,383
66,801
95,051
83,503
73,173
117,949
109,114
198,279
181,679
165,894
146,345
128,472
106,765
113,762
94,865
84,991
73,931
67,344
64,937
48,638
27,927
19,440
8,263
6,037
4,678
3,550
3,5504,6786,0378,26319,44027,92748,63864,93767,34473,93184,99194,865113,762106,765128,472146,345165,894181,679198,279109,114117,94973,17383,50395,05166,80176,38387,461105,606116,559126,81394,494106,348117,122128,012141,682153,724173,361124,038131,64845,23749,10955,34863,32571,75429,47845,60363,34683,404105,640122,380140,873108,108122,276132,821130,86261,52067,45074,45645,84049,7368,1035,4317,87312,57316,81522,45829,00436,72642,80148,52154,18529,51235,29537,7756,3089,49211,3121000000011263410000
   > Total Current Assets 
0
0
0
9
3
1
5
1
0
0
0
0
0
0
0
0
0
1
10,950
9,093
5,875
37,349
34,813
28,873
53,275
47,508
41,626
35,528
27,823
21,325
15,769
11,706
7,006
4,696
7,450
49,193
45,356
73,941
66,823
60,816
129,971
131,298
120,417
106,105
138,811
119,442
102,581
80,276
60,561
43,030
27,275
70,297
62,001
54,024
47,814
44,087
130,603
123,080
172,480
152,521
140,389
126,709
115,677
104,884
92,750
125,130
114,888
90,783
72,115
52,993
47,161
84,285
74,093
65,859
115,599
105,492
191,620
173,176
155,071
130,589
112,710
89,407
96,554
78,831
69,772
61,361
55,505
53,799
38,184
18,778
12,869
8,261
6,037
4,678
3,550
3,5504,6786,0378,26112,86918,77838,18453,79955,50561,36169,77278,83196,55489,407112,710130,589155,071173,176191,620105,492115,59965,85974,09384,28547,16152,99372,11590,783114,888125,13092,750104,884115,677126,709140,389152,521172,480123,080130,60344,08747,81454,02462,00170,29727,27543,03060,56180,276102,581119,442138,811106,105120,417131,298129,97160,81666,82373,94145,35649,1937,4504,6967,00611,70615,76921,32527,82335,52841,62647,50853,27528,87334,81337,3495,8759,09310,950100000000015139000
       Cash And Cash Equivalents 
0
0
0
6
1
0
5
0
0
0
0
0
0
0
0
0
0
1
10,741
8,881
1,079
32,577
32,962
26,855
52,701
46,690
40,939
35,029
27,487
21,087
15,192
11,379
6,768
4,543
7,080
48,839
45,044
73,662
66,471
60,392
124,037
130,282
118,933
104,713
128,008
110,391
95,333
73,306
55,655
38,932
23,631
68,204
60,385
53,001
46,122
42,803
129,684
118,550
163,843
140,717
124,846
109,004
94,683
81,053
66,447
97,194
84,406
70,946
51,108
40,404
31,728
61,729
51,487
43,563
88,419
79,741
171,002
153,521
135,471
115,069
100,056
76,746
91,725
76,054
68,255
60,011
37,807
39,058
23,496
18,317
11,944
6,062
4,145
2,463
1,683
1,6832,4634,1456,06211,94418,31723,49639,05837,80760,01168,25576,05491,72576,746100,056115,069135,471153,521171,00279,74188,41943,56351,48761,72931,72840,40451,10870,94684,40697,19466,44781,05394,683109,004124,846140,717163,843118,550129,68442,80346,12253,00160,38568,20423,63138,93255,65573,30695,333110,391128,008104,713118,933130,282124,03760,39266,47173,66245,04448,8397,0804,5436,76811,37915,19221,08727,48735,02940,93946,69052,70126,85532,96232,5771,0798,88110,741100000000005016000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,553
1,536
1,555
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000000000000000001,5551,5364,5534,50000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
79
79
0
0
13
58
72
31
449
145
27
32
208
145
62
89
369
446
1,060
15
25
21
67
44
13
19
18
663
1,021
1,864
854
1,460
3,441
3,330
782
4,072
5,428
4,665
5,006
7,626
1,510
1,111
0
1,111
2,911
4
0
4
0
1
1
4
0
041104042,9111,11101,1111,5107,6265,0064,6655,4284,0727823,3303,4411,4608541,8641,02166318191344672125151,060446369896214520832271454493172581300797905,0000000000000000000000000000000000010000000
       Other Current Assets 
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
210
212
296
219
315
463
574
818
687
499
336
238
577
327
238
153
370
354
312
279
352
424
934
1,016
1,405
1,313
10,803
9,051
7,235
6,912
4,834
4,067
3,195
1,948
1,589
991
1,484
1,139
857
4,441
8,268
11,358
14,483
17,690
20,969
23,810
26,236
27,892
30,469
19,818
20,989
11,926
14,412
20,692
21,752
20,836
23,739
22,421
19,836
15,583
14,172
10,855
7,648
5,035
3,319
1,666
1,517
1,350
14,787
799
750
457
925
2,198
1,891
2,211
1,867
1,8672,2111,8912,19892545775079914,7871,3501,5171,6663,3195,0357,64810,85514,17215,58319,83622,42123,73920,83621,75220,69214,41211,92620,98919,81830,46927,89226,23623,81020,96917,69014,48311,3588,2684,4418571,1391,4849911,5891,9483,1954,0674,8346,9127,2359,05110,8031,3131,4051,016934424352279312354370153238327577238336499687818574463315219296212210000000000000020000
   > Long-term Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
362
400
433
427
482
639
910
1,013
1,175
1,199
1,181
1,133
1,046
867
867
735
653
543
484
515
627
704
891
1,523
1,859
2,003
2,062
2,938
3,059
3,128
2,785
2,573
2,203
1,457
1,324
1,324
1,295
1,150
1,045
958
881
1,203
1,293
1,303
1,445
1,464
1,744
1,683
1,671
14,823
15,346
23,390
19,640
10,766
9,410
7,314
2,350
3,622
6,659
8,503
10,823
15,756
15,762
17,358
17,208
16,034
15,219
12,570
11,839
11,138
10,454
9,149
6,571
2
2
0
0
00226,5719,14910,45411,13811,83912,57015,21916,03417,20817,35815,76215,75610,8238,5036,6593,6222,3507,3149,41010,76619,64023,39015,34614,8231,6711,6831,7441,4641,4451,3031,2931,2038819581,0451,1501,2951,3241,3241,4572,2032,5732,7853,1283,0592,9382,0622,0031,8591,5238917046275154845436537358678671,0461,1331,1811,1991,1751,013910639482427433400362000000000011111000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233
270
302
295
295
451
601
661
719
746
727
675
589
489
489
406
324
255
196
216
230
253
443
549
886
1,141
1,177
1,982
2,108
1,994
1,909
1,713
1,336
801
679
683
654
531
426
321
262
581
667
682
825
843
1,124
1,062
1,047
1,211
1,244
1,332
1,344
1,097
2,556
2,315
2,111
3,382
5,863
7,629
9,947
14,881
15,447
16,977
16,841
15,361
14,551
12,028
11,297
10,596
9,912
8,648
6,571
2
2
0
0
00226,5718,6489,91210,59611,29712,02814,55115,36116,84116,97715,44714,8819,9477,6295,8633,3822,1112,3152,5561,0971,3441,3321,2441,2111,0471,0621,1248438256826675812623214265316546836798011,3361,7131,9091,9942,1081,9821,1771,141886549443253230216196255324406489489589675727746719661601451295295302270233000000000000000000
       Intangible Assets 
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000011111000
       Other Assets 
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
875
315
381
367
673
668
542
542
542
0
501
0
0
0
0
0
0000050105425425426686733673813158750000000000000000000000000000000000000000000000000000000000000000000000000100000
> Total Liabilities 
0
0
0
14
12
6
0
2
7
18
15
19
26
14
15
21
18
10
1,748
2,290
2,024
2,677
3,321
2,979
3,398
3,867
5,106
6,357
6,790
6,242
5,761
5,834
4,136
3,753
4,180
21,632
34,454
19,738
25,246
30,967
48,910
48,693
38,164
36,501
43,173
46,744
46,612
34,959
25,453
26,271
25,847
22,371
21,593
17,632
12,632
11,396
11,045
13,597
79,520
66,353
63,869
180,002
59,726
183,646
59,955
56,853
57,289
202,412
61,571
61,190
62,786
9,487
9,287
11,178
11,823
109,114
17,942
18,265
20,976
22,363
22,831
18,484
45,055
36,808
35,869
33,751
35,231
26,382
19,129
6,277
5,540
1,956
1,240
907
826
8269071,2401,9565,5406,27719,12926,38235,23133,75135,86936,80845,05518,48422,83122,36320,97618,26517,942109,11411,82311,1789,2879,48762,78661,19061,571202,41257,28956,85359,955183,64659,726180,00263,86966,35379,52013,59711,04511,39612,63217,63221,59322,37125,84726,27125,45334,95946,61246,74443,17336,50138,16448,69348,91030,96725,24619,73834,45421,6324,1803,7534,1365,8345,7616,2426,7906,3575,1063,8673,3982,9793,3212,6772,0242,2901,74810182115142619151872061214000
   > Total Current Liabilities 
0
0
0
10
8
0
0
0
0
18
15
19
26
14
15
21
18
10
1,748
2,255
1,988
2,640
3,281
2,938
3,357
3,824
5,070
6,306
6,731
6,181
5,701
5,776
3,956
3,375
3,514
3,095
2,833
2,305
4,106
3,612
6,544
8,691
11,770
13,363
14,330
17,776
21,736
18,864
20,362
20,997
13,362
7,791
7,354
10,788
11,700
10,826
10,492
13,110
29,627
18,123
17,274
16,035
15,744
15,809
17,464
15,988
18,189
20,856
10,062
9,314
60,183
9,483
8,339
10,400
11,176
12,526
16,579
17,112
19,321
18,368
18,961
13,593
28,173
16,041
21,234
26,775
32,869
24,166
17,063
5,052
4,676
1,956
1,240
907
826
8269071,2401,9564,6765,05217,06324,16632,86926,77521,23416,04128,17313,59318,96118,36819,32117,11216,57912,52611,17610,4008,3399,48360,1839,31410,06220,85618,18915,98817,46415,80915,74416,03517,27418,12329,62713,11010,49210,82611,70010,7887,3547,79113,36220,99720,36218,86421,73617,77614,33013,36311,7708,6916,5443,6124,1062,3052,8333,0953,5143,3753,9565,7765,7016,1816,7316,3065,0703,8243,3572,9383,2812,6401,9882,2551,7481018211514261915180000810000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,112
146
644
660
677
774
828
838
866
819
759
765
12,747
8,597
14,738
20,576
23,210
17,323
11,563
339
307
0
0
0
0
000030733911,56317,32323,21020,57614,7388,59712,74776575981986683882877467766064414640,1120000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,037
7,868
13,993
20,051
22,668
16,765
10,988
0
0
0
0
0
0
00000010,98816,76522,66820,05113,9937,86812,0370000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
1
0
0
8
5
5
0
10
10
477
836
545
627
1,144
776
956
1,489
1,638
2,909
2,648
1,900
2,228
2,639
1,621
1,606
1,559
1,789
1,468
1,143
1,088
1,031
1,853
1,784
2,160
1,727
1,984
1,470
4,248
1,509
983
1,165
891
422
578
447
1,953
2,004
779
3,143
4,154
2,008
1,908
2,031
1,814
156
226
81
1,524
4,417
606
588
1,269
707
859
941
926
906
396
1,082
2,619
960
4,190
982
1,463
1,368
605
474
1,984
1,389
1,380
1,479
1,298
616
597
365
458
4583655976161,2981,4791,3801,3891,9844746051,3681,4639824,1909602,6191,0823969069269418597071,2695886064,4171,524812261561,8142,0311,9082,0084,1543,1437792,0041,9534475784228911,1659831,5094,2481,4701,9841,7272,1601,7841,8531,0311,0881,1431,4681,7891,5591,6061,6212,6392,2281,9002,6482,9091,6381,4899567761,14462754583647710100558001000000000
       Other Current Liabilities 
0
0
0
10
8
0
0
0
0
17
15
19
18
9
10
21
7
0
1,271
1,419
1,443
2,013
2,137
2,162
2,402
2,335
3,432
3,396
4,083
4,281
3,473
3,137
2,335
1,730
1,909
1,261
1,322
1,139
2,978
2,538
3,862
6,084
8,789
10,821
11,534
15,502
16,682
16,555
18,579
19,032
11,671
6,569
5,976
8,008
8,047
7,462
8,625
9,151
18,540
9,254
8,877
7,615
7,541
9,264
10,849
9,518
10,276
10,050
8,980
8,726
49,513
8,776
644
8,799
9,573
10,846
15,355
15,192
15,836
16,589
14,012
11,846
13,963
6,076
5,891
5,725
7,675
5,454
4,120
3,234
1,773
0
643
542
368
36854264301,7733,2344,1205,4547,6755,7255,8916,07613,96311,84614,01216,58915,83615,19215,35510,8469,5738,7996448,77649,5138,7268,98010,05010,2769,51810,8499,2647,5417,6158,8779,25418,5409,1518,6257,4628,0478,0085,9766,56911,67119,03218,57916,55516,68215,50211,53410,8218,7896,0843,8622,5382,9781,1391,3221,2611,9091,7302,3353,1373,4734,2814,0833,3963,4322,3352,4022,1622,1372,0131,4431,4191,2710721109181915170000810000
   > Long-term Liabilities 
0
0
0
4
4
6
0
2
7
1
0
0
8
5
5
0
10
10
477
36
36
37
40
41
41
44
36
51
59
60
61
58
180
378
666
18,537
31,621
17,433
21,140
27,355
42,366
40,002
26,394
23,138
28,843
28,968
24,876
16,095
5,091
5,274
12,485
14,580
14,239
6,844
932
570
553
487
49,893
48,230
46,595
163,967
43,982
42,516
42,491
40,865
39,100
37,564
51,509
51,876
2,603
4
948
778
647
1,578
1,363
1,153
1,655
3,995
3,870
4,891
16,882
20,767
14,635
6,976
2,362
2,216
2,066
1,225
864
0
0
0
0
00008641,2252,0662,2162,3626,97614,63520,76716,8824,8913,8703,9951,6551,1531,3631,57864777894842,60351,87651,50937,56439,10040,86542,49142,51643,982163,96746,59548,23049,8934875535709326,84414,23914,58012,4855,2745,09116,09524,87628,96828,84323,13826,39440,00242,36627,35521,14017,43331,62118,5376663781805861605951364441414037363647710100558001720644000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,323
4,472
0
0
0
0
0
0
0
0
0
0000000004,47210,323000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
28
28
28
0
0
0
0
0
0
0
00000002828280-100000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-4
-8
-14
-3
-9
-11
-17
-15
-19
-26
-14
-15
-21
-18
-9
9,564
7,202
4,284
35,098
31,974
26,533
50,787
44,654
37,695
30,370
22,214
16,217
11,053
6,739
3,737
1,678
3,923
28,104
11,386
54,718
42,204
30,553
81,952
84,128
84,112
71,607
97,700
75,636
59,028
48,445
37,893
19,332
3,631
49,383
41,732
37,716
36,477
33,841
120,603
110,441
93,841
87,371
77,813
-51,990
57,396
-77,298
34,539
69,960
59,270
-96,806
25,890
15,193
4,015
85,564
74,216
61,995
106,126
95,010
180,337
163,414
144,918
123,982
105,641
88,281
68,707
58,057
49,122
40,180
32,113
38,555
29,509
21,650
13,900
6,307
4,797
3,771
2,724
2,7243,7714,7976,30713,90021,65029,50938,55532,11340,18049,12258,05768,70788,281105,641123,982144,918163,414180,33795,010106,12661,99574,21685,5644,01515,19325,890-96,80659,27069,96034,539-77,29857,396-51,99077,81387,37193,841110,441120,60333,84136,47737,71641,73249,3833,63119,33237,89348,44559,02875,63697,70071,60784,11284,12881,95230,55342,20454,71811,38628,1043,9231,6783,7376,73911,05316,21722,21430,37037,69544,65450,78726,53331,97435,0984,2847,2029,564-9-18-21-15-14-26-19-15-17-11-9-3-14-8-4000
   Common Stock
0
0
0
89
89
0
0
120
120
120
130
130
130
156
156
156
169
184
7
7
7
15
15
15
21
21
21
21
21
21
21
22
22
22
26
42
42
49
49
48
66
68
68
69
80
80
80
83
84
84
84
100
101
101
103
104
128
131
131
132
132
132
132
132
132
142
142
143
142
142
142
161
162
162
181
182
214
214
214
215
215
216
216
216
216
216
216
240
241
241
241
0
16
2
2
22160241241241240216216216216216216215215214214214182181162162161142142142143142142132132132132132132131131128104103101101100848484838080806968686648494942422622222221212121212121151515777184169156156156130130130120120120008989000
   Retained Earnings Total Equity000000-890,675-880,627-871,468-862,572-852,640000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
21
21
21
21
0
0
0
0
0
0
0
15,071
20,504
20,504
20,504
20,504
20,504
20,504
20,504
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-119,045
0
-125,321
0
0
0
-143,992
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000-143,992000-125,3210-119,04500000000000000000000000000000020,50420,50420,50420,50420,50420,50420,50415,071000000021212121000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
901,546
902,536
903,365
918,942
919,943
0
0
0
0
0
0
000000919,943918,942903,365902,536901,546000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
30
33
157
176
65
69
73
82
86
70
79
83
88
114
118
22,460
22,559
22,860
59,031
59,362
44,668
68,524
68,936
69,300
69,674
70,142
70,645
71,026
91,778
90,548
90,889
96,005
119,206
120,141
154,427
154,118
154,319
244,708
257,606
258,392
259,130
309,682
311,231
312,447
332,086
334,332
334,463
335,474
390,114
392,173
393,733
398,585
406,349
571,318
575,364
576,934
579,939
582,400
583,797
582,225
580,567
578,571
622,052
619,232
615,493
613,302
609,247
604,653
651,732
653,817
656,216
774,324
778,953
882,541
884,214
886,033
887,868
891,081
896,390
899,549
900,693
901,546
902,536
903,365
918,942
919,943
920,857
921,583
0
922,230
922,346
922,426
922,426922,346922,2300921,583920,857919,943918,942903,365902,536901,546900,693899,549896,390891,081887,868886,033884,214882,541778,953774,324656,216653,817651,732604,653609,247613,302615,493619,232622,052578,571580,567582,225583,797582,400579,939576,934575,364571,318406,349398,585393,733392,173390,114335,474334,463334,332332,086312,447311,231309,682259,130258,392257,606244,708154,319154,118154,427120,141119,20696,00590,88990,54891,77871,02670,64570,14269,67469,30068,93668,52444,66859,36259,03122,86022,55922,4601181148883797086827369651761573330000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.